Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
Mingxia Jiang1, Liping Zhao1, Xiaoming Cui1
1College of Pharmacy, Weifang Medical University, Weifang 261053, China.
Introduction:
Tumor vaccine has been a research boom for cancer immunotherapy, while its therapeutic outcome is severely depressed by the vulnerable in vivo delivery efficiency. Moreover, tumor immune escape is also another intractable issue, which has badly whittled down the therapeutic efficiency.
Objectives:
Our study aims to solve the above dilemmas by cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Methods:
The minimalist antigen and adjuvant co-delivery nanovaccine was developed by employing natural polycationic protamine (PRT) to carry the electronegative ovalbumin (OVA) antigen and unmethylated Cytosine-phosphorothioate-Guanine (CpG) adjuvant via convenient chemical bench-free "green" preparation without chemical-synthesis and no organic solvent was required, which could preserve the immunological activities of the antigens and adjuvants. On that basis, PD-1 antibody (aPD-1) was utilized to block the tumor immune escape and cooperate with the nanovaccine by maintaining the tumoricidal-activity of the vaccine-induced T cells.
Results:
Benefited from the polycationic PRT, the facile PRT/CpG/OVA nanovaccine displayed satisfactory delivery performance, involving enhanced cellular uptake in dendritic cells (DCs), realizable endosomal escape and promoted stimulation for DCs' maturation. These features would be helpful for the antitumor immunotherapeutic efficiency of the nanovaccine. Furthermore, the cooperation of the nanovaccine with aPD-1 synergistically improved the immunotherapy outcome, profiting by the cooperation of the "T cell induction" competency of the nanovaccine and the "T cell maintenance" function of the aPD-1.
Conclusion:
This study will provide new concepts for the design and construction of facile nanovaccines, and contribute valuable scientific basis for cancer immunotherapy.
Insights
This study developed a novel nanovaccine using protamine to deliver antigens and adjuvants, enhancing cancer immunotherapy. Combining this nanovaccine with PD-1 blockade effectively combats tumor immune escape and improves therapeutic outcomes.
Area of Science:
- Nanotechnology in Cancer Immunotherapy
- Drug Delivery Systems
- Immunology
Background:
- Cancer immunotherapy faces challenges with *in vivo* delivery efficiency and tumor immune escape.
- Existing therapeutic outcomes are often limited by these delivery and immune evasion issues.
Purpose of the Study:
- To address limitations in cancer immunotherapy by combining a minimalist nanovaccine with PD-1 blockade.
- To develop an effective and feasible approach for cancer treatment.
Main Methods:
- A minimalist nanovaccine was created using protamine (PRT) to co-deliver ovalbumin (OVA) antigen and CpG adjuvant via a green, bench-free method.
- The nanovaccine was combined with a PD-1 antibody (aPD-1) to block tumor immune escape and maintain T cell activity.
Main Results:
- The PRT/CpG/OVA nanovaccine demonstrated enhanced cellular uptake, endosomal escape, and dendritic cell maturation, improving antitumor immunotherapeutic efficiency.
- The combination therapy synergistically enhanced immunotherapy by integrating the nanovaccine's T cell induction with aPD-1's T cell maintenance.
Conclusions:
- This study introduces a facile nanovaccine design for improved cancer immunotherapy.
- The findings provide a valuable scientific basis for developing novel cancer treatment strategies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...